
Hemorrhagic cystitis, a condition marked by persistent hematuria post cancer treatment, remains enigmatic. Acrolein toxicity from chemotherapy and fibrosis/vascular remodeling after radiation are suspected culprits. Standard care still eludes, but short-term successes seen in cohort studies with fulguration, hyperbaric oxygen, botulinum toxin A, and intravesical therapies offer hope. Excitingly, liposomal tacrolimus emerges as a promising contender for further research.
Like
Save
Share